Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter formulary coverage & PA Policy Up…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy N/A

    Ambetter Health Formulary (Prescription Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Centene policy alerts

    Know when Centene releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs the Ambetter Health prescription drug formulary (covered brand and generic drugs), formulary tiers, prior authorization and quantity/age limits, and specialty drug handling for Ambetter members. It affects providers prescribing medications and pharmacies dispensing under Ambetter plans.

    Policy Summary
    PayerCentene
    PolicyAmbetter Health Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionSubmit a Prior Authorization form when a listed product is marked 'PA' to obtain approval before dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Tier 0–4Formulary copay tiers described
    PAPrior authorization required
    7-dayOpioid new-start limits
    Tier 4Specialty tier handling
    EN/ESBilingual

    Formulary Coverage Rules & Product-Level Controls

    Formulary coverage rules

    Covered when ALL of the following are met:

    Formulary coverage general rules: Drug is listed on the Ambetter formulary or coverage is granted per member's specific benefit design; generics are preferred when available; not all dosage forms/strengths are necessarily covered.

    See general formulary description

    Prior authorization for non-formulary or restricted drugs: If the drug is non‑formulary or the formulary line indicates 'PA', a prior authorization must be obtained before coverage; urgent requests are responded to within 24 hours and non‑urgent within 72 hours (unless state law requires faster response).

    See Prior Authorization for Non‑Formulary Drugs

    Opioid new‑start limits: For products annotated 'New starts limited to 7 day supply', new opioid starts are limited to up to two 7‑day fills in any 28‑day period and up to 28 non‑consecutive days' supply in any 90‑day period; fills beyond these limits require prior authorization.
    Policy Summary
    PayerCentene
    PolicyAmbetter Health Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionSubmit a Prior Authorization form when a listed product is marked 'PA' to obtain approval before dispensing.
    SourceLink
    On This Page
    Formulary Coverage Rules & Product-Level ControlsCodes, Abbreviations, and Quantity ExamplesPrior Authorization, Step Therapy, and Documentation RequirementsKey Terms and Formulary TieringInitial Prescribing Limits and New-Start ControlsContinuation / Ongoing TherapyStep Therapy Notes and Affected ProductsQuantity Limits by Product (Selected Examples)Specialty Pharmacy and Site RestrictionsFormulary Purpose and ScopeBiosimilar / Brand Mappings
    Two 7‑day fills per 28 days; ≤28 days supply per 90 days

    See Opioid Medications policy

    Utilization controls for specific formulations

    Covered when ANY of the following utilization conditions are satisfied:

    Butalbital-containing product utilization control: New starts for certain butalbital‑containing combination products are limited to a 7‑day supply; per‑product QL values apply as listed (e.g., QL(6 EA daily) where shown).7 day supply for new starts

    See butalbital entries

    Age and quantity constraints

    Covered when product-level age and quantity constraints are met:

    Age restrictions: If an entry includes an age limit (AL), member must meet the minimum age (examples in formulary include AL(At least 6 yrs old) and AL(At least 12 yrs old)).>= stated age

    See per‑product AL values

    Quantity limits (QL): If an entry includes 'QL(...)' the specified quantity limit applies (examples include QL(30 ML daily), QL(2 EA daily), QL(280 ML per 56 days)); QL format may be per day, per fill, or per period as listed.See QL value on drug line

    Varies by product; apply the exact QL shown

    Formulary coverage with utilization limits

    Coverage for opioid and related analgesic products is subject to the following:

    Opioid/new‑start and QL controls: Opioid products are assigned formulary tiers and many have quantity limits and new‑start 7‑day supply restrictions; some strengths/formulations additionally require prior authorization (PA).New‑start 7‑day limits and per‑product QL as listed

    Apply per listed product entries

    PA/SP flagged agents

    Covered when ANY of the following apply:

    PA or SP flagged agents: If a formulary line includes 'PA' or 'SP', prior authorization or site/specialty prior authorization is required before coverage is approved.

    Examples: entries annotated SP; PA (see antineoplastic/antimalarial lines)

    Quantity-limited agents

    Covered when the specified quantity limits are not exceeded:

    Quantity‑limited agent rule: When a drug entry specifies 'QL(...)' that quantity limit governs coverage (examples extracted: QL(4 EA daily); QL(1 EA daily); QL(24 EA per fill mail)).Apply the per‑product QL value shown

    Multiple QL formats (daily, per fill, per period) appear in the formulary

    Coverage contingent on PA/QL/SP

    Coverage is provided when ALL drug‑specific conditions are satisfied:

    Drug‑specific coverage conditions: Coverage for a listed drug requires adherence to all utilization controls on the formulary line (e.g., quantity limits, prior authorization, specialty pharmacy/site requirements).See QL/PA/SP on each drug line

    Many antineoplastic and specialty agents include SP and/or PA

    Formulary tier and utilization controls

    Covered when ALL of the following are met:

    Tier assignment and utilization controls: Drugs placed on a formulary tier are subject to the utilization controls shown (QL, PA, SP); coverage requires meeting the listed controls and any per‑tier restrictions (specialty tier drugs may require specialty fulfillment).

    See Tier and ILimits on each product line

    Formulary tiering and utilization controls (partial)

    Covered when ALL of the following product-level requirements are met:

    Tier/age/quantity/step/PA adherence: Member coverage depends on the drug's tier assignment and meeting any ILimits such as AL (age limit), QL (quantity limit), PA (prior authorization), or ST (step therapy) specified on the formulary line.

    Examples: topical agents with AL(At least 12 yrs old), QL values, or ST flags

    General coverage for listed topical and related products

    Covered when ALL of the following are satisfied:

    Topical and related product coverage conditions: Topical products are listed with a Tier and may have associated QL, PA, and ST flags; coverage requires compliance with those listed controls (e.g., QL(3 GM daily), ST where shown).

    Follow specific Tier/QL/PA/ST for each topical entry

    The formulary is a curated prescription drug list and is not intended to be a complete listing of every covered product or every dosage form or strength. Coverage for a listed drug depends on the member's specific benefit design, the drug's listed tier, and any line-level utilization controls (for example, generics are preferred as first-line options). Providers should verify plan-specific benefit limits and any drug-specific requirements (QL, PA, AL, ST, SP) shown on the formulary prior to prescribing or dispensing.

    Within this segment there are no explicit formulary exclusions listed. Drug rows in the extracted portion do not state any products as categorically excluded; however, plan-specific benefit designs may still exclude certain items despite their appearance in the document.

    The partial section reviewed does not contain explicit exclusions. Entries shown include standard tiering and ILimits fields but no statements declaring a product or class to be excluded from coverage.

    Some entries are labeled for limited indications; for example, certain antimalarial agents are annotated as "Covered for malaria treatment only", demonstrating indication‑limited coverage rather than broad coverage for all uses.

    This document segment contains no explicit exclusions. Listed products in the excerpt show utilization controls (e.g., QL, PA, SP) but do not include statements excluding coverage outright.

    In the excerpted material there are no explicit statements labeling drugs as not covered. Coverage appears contingent on meeting listed utilization controls (PA, QL, SP) rather than on categorical exclusion language.

    The formulary requires prior authorization for non‑FDA approved uses of certain products. Where an entry indicates non‑FDA uses require PA, providers must obtain the PA to secure coverage for that off‑label use.

    No explicit 'Not Medically Necessary' (NMN) statements are present in this segment of the formulary extract.

    This partial section contains no explicit 'not medically necessary' determinations; coverage references are tied to tiering and utilization controls rather than NMN language.

    No NMN statements are visible in the reviewed excerpt; product coverage in this area is expressed via tiers and ILimits (QL, PA) rather than explicit NMN language.

    When a product is used for indications that are not FDA‑approved, the formulary notes that such uses require prior authorization; absent PA, those non‑FDA uses are flagged and may be treated as not covered unless authorized.

    Codes, Abbreviations, and Quantity Examples

    Formulary codes/limits/abbreviationsmixed
    PAPrior Authorization
    QLQuantity Limit
    ALAge Limit
    STStep Therapy
    NFNon-formulary
    SPSpecialty
    SFSplit Fill
    NDC/HCPCS/CPT not providedmixed
    No codes listed
    Drug entries (no standardized billing codes provided)mixed
    No codes listed
    No procedure/diagnosis/billing codes present in this sectionmixed
    No codes listed
    Formulary drug name referencesNDC
    XIFAXAN 200 MGlisted as a 'prug Name' in several entries
    ALINIA SUSRlisted as a 'prug Name' for valsartan-hydrochlorothiazide entry
    VECAMYLlisted as drug name with ILimits = PA
    Referenced biosimilar/brand namesNDC
    MVASIprug Name for fludarabine phosphate SOLN
    ZIRABEVprug Name for SOLN fludarabine phosphate
    LOQTORZIprug Name for gemcitabine hcl SOLR
    Drug dose entries extracted as-codedmixed
    240 MGFIRMAGON (240 MG DOSE) - quantity limit noted as QL(0.143 EA daily); SP; PA
    Dose-level entriesmixed
    3.5 MGBORTEZOMIB SOLR IV 3.5 MG - listed with QL references
    Quantity limit entries presentmixed
    QL(8 EA daily)Quantity limit for INTELENCE 25 MG
    QL(2 EA daily)Quantity limit for ISENTRESS HD TABS / ISENTRESS TABS
    QL(6 EA daily)Quantity limit for ISENTRESS CHEW
    QL(12.5 ML)Quantity limit for KALETRA SOLN
    QL(30 ML)Quantity limit for lamivudine SOLN
    Utilization management codesmixed
    PAPrior authorization required
    SPSpecialty Pharmacy
    Formulary quantity-limit codes (examples from test supplies)mixed
    QL(3.34 EA daily)Quantity limit example for TRUE METRIX / test strips as listed
    QL(6 EA daily)Quantity limit example for PRECISION XTRA KETONE listed
    QL(4 EA daily)Quantity limit example for KETOSTIX STRP
    inv-33: Opioid new-start limits
    Opioid new-start ruleNew opioid starts limited to up to two 7‑day fills during any 28‑day period and up to a total of 28 non‑consecutive days' supply in any 90‑day period; fills beyond these limits require Prior Authorization.
    Applies toAll opioid medications identified with 'New starts limited to 7 day supply' on the formulary.
    Authorization for excess daysProviders may submit a Prior Authorization request for fills exceeding the stated limits.
    inv-34: Quantity limits examples
    Example QL (EA daily)Examples shown include QL(4 EA daily), QL(2 EA daily), QL(3 EA daily), QL(6 EA daily).
    Example QL (ML daily)Examples shown include QL(30 ML daily), QL(60 ML daily), QL(180 ML daily).
    Per‑period examplesExamples include QL(280 ML per 56 days) and QL(24 EA per fill mail).
    inv-35: Package/Fill limits
    Package/180‑day fill limitsSome starter kits and pack products listed with 'package(s) per 180 day(s) retail' or 'max fill(s) per 180 day(s)' (e.g., CYLTEZO/HUMIRA starter kits).
    Max fills per periodCertain products specify a numeric max fill(s) per 180 days for retail and/or mail fulfillment.
    Starter kit restrictionsStarter/pack presentations may be limited to 1 max fill(s) per 180 day(s) retail for specific starter kits.
    inv-36: Injectable ML limits
    Injectable ML exampleExamples include QL(3.6 ML per 28 day(s) retail; 4 ML per 28 days mail) for certain injectables (e.g., ACTEMRA presentations).
    Retail vs mail ML limitsSome injectable products have different ML limits for retail versus mail fills (retail vs mail per 28 days).
    SP and PA annotationsInjectable ML limits often appear alongside SP and/or PA requirements when applicable.
    inv-37: Daily quantity limits examples
    Common daily EA limitsExamples include QL(6 EA daily), QL(10 EA daily), QL(13 EA daily).
    Common daily ML limitsExamples include QL(180 ML daily) and QL(100 ML daily) noted for liquid formulations.
    Daily QL with PASome daily quantity limits are combined with PA annotations for select strengths/formulations.
    inv-38: Example quantity limits
    Per‑fill count examplesExamples include QL(60 EA per fill retail; 60 per fill mail) and QL(45 EA per fill retail).
    Per‑retail max examplesExamples include QL(2 EA per retail; 2 max per 30 day(s) retail) for certain products like naloxone formulations.
    Daily plus max‑fill combosSome entries show daily QL with additional max fill rules (e.g., daily QL plus 3 max fills per 365 days retail).
    inv-39: Examples of quantity limits
    Antifungal and other specific QLsExamples: itraconazole CAPS QL(4 EA daily); cholestyramine POWD QL(24 GM daily); fluvastatin CAPS QL(2 EA daily).
    Liquid antifungal QLitraconazole SOLN listed with QL(20 ML).
    Formulation‑specific QLsEntries show QL tied to formulation and unit (EA, ML, GM) per product line.
    inv-40: Example quantity limits
    Short course antibiotic QLsExample: linezolid TABS QL(2 EA daily); other antibiotics may show QL(24 EA per fill mail) or QL(1 EA daily).
    Nitrofurantoin exampleNitrofurantoin listed with QL(1 EA daily).
    Mail fill examplesSome anti‑infective entries specify mail fill per‑period limits (e.g., 24 EA per fill mail).
    inv-41: Examples of quantity limits
    Antineoplastic QL patternsMany antineoplastic agents list QL values such as QL(1 EA daily), QL(2 EA daily), QL(0.143 ML daily) often with SP and PA annotations.
    SP/PA accompanimentQuantity limits for specialty oncology agents frequently appear alongside SP and PA requirements.
    Dose‑dependent QLsQL values vary by daily dose specification and by specific drug formulation/dose.
    inv-42: Common quantity limits
    Common QL setFrequently seen QLs include QL(1 EA daily), QL(2 EA daily), QL(4 EA daily), and volumetric limits such as QL(30 ML) or QL(125 ML).
    Use with PA/SPThese common quantity limits may be enforced together with PA or SP designations on formulary lines.
    Applies across classesCommon QL values appear across multiple therapeutic classes (oral solids, liquids, injectables).
    inv-43: Sample quantity limits
    Sample per‑period and daily QLsExamples include QL(3 EA per 28 day(s) retail; 9 EA per 84 days mail), QL(7.5 ML daily), QL(6 EA daily), QL(8 ML daily).
    Contraceptive exampleLevonorgestrel‑ethinyl estradiol (triphasic) listed QL(3 EA per 28 day(s) retail; 9 EA per 84 days mail).
    Topical/GM examplesTopical examples referenced in sample limits overlap with daily GM rules (see topical blocks).
    inv-44: Age limits examples
    Age limit examplesEntries include age limits such as AL(At least 12 yrs old); some topical entries note 'Up to 30 yrs' where applicable.
    Topical age constraintsTopical acne and dermatologic products frequently include AL(At least 12 yrs old) for use and coverage.
    Documentation implicationAge limits must be met and documented when dispensing products with AL annotations.
    inv-45: Quantity limits examples
    Topical quantity examplesExamples include QL(15 GM per 30 day(s) retail), QL(60 GM per 30 day(s)), QL(3 GM daily).
    Combination topical rulesSome topical combination products pair AL (age limit) with QL and may require PA or ST depending on the entry.
    Per‑fill vs daily topical QLsTopical entries show both per‑30‑day fill limits and daily gram (GM) limits depending on formulation.
    inv-46: Daily topical quantity limits
    Daily topical QL examplesDaily topical examples include QL(1 GM daily), QL(3 GM daily), QL(4 GM daily), QL(15.15 GM daily).
    Topical unit conventionsTopical limits are expressed in grams (GM) or milliliters (ML) per day or per fill as specified per product line.
    Support for dosingDocumentation should support prescribed dosing consistent with these daily topical quantity limits.

    Prior Authorization, Step Therapy, and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization (PA) is required for many listed products and selected agents across the formulary. Claims for drugs requiring PA may be denied at point-of-sale or on claim adjudication if PA is not obtained.

    • PA required for many antineoplastics and other high‑tier oncology agents (SP; PA).
    • PA indicated for selected specialty and high‑tier products (examples: injectable biologics, enzyme therapies, orphan drugs).
    • PA required for select pulmonary hypertension agents (e.g., ambrisentan, bosentan, tadalafil, sildenafil, UPTRAVI, TYVASO) and other specialty pulmonary products.
    • Certain topical and non‑FDA uses require PA; non‑FDA approved uses may be denied without prior authorization.
    Documentation Required

    Documentation and Quantity/Age Requirements

    Prior authorization requests must include documentation that supports medical necessity and adherence to quantity limits (QL) and age limits (AL) where applicable. Examples of required documentation include diagnosis, prior therapies tried (for ST requirements), dosing and duration, and rationale for non‑formulary or non‑FDA use.

    • Document how requested quantity relates to QL and why greater quantity is needed.
    • Provide patient age when an AL applies.
    • Supply clinical notes showing prior trials and failures when step therapy (ST) is required.
    • For specialty products, include site of care, administration plan, and prior authorization forms as applicable.
    Prior Authorization

    Prior Authorization Submission and Response Times; Denial Notice

    Submission and response times: urgent PA requests will be responded to within 24 hours of receipt of all necessary information; non‑urgent requests will be responded to within 72 hours unless a state law requires a faster response. If a request is denied or incomplete, the notice will explain the specific reasons for denial or identify missing information required to complete the request.

    • If disapproved, notice of disapproval will state specific reasons and any missing material information.
    • Follow the payer’s PA form and fax/phone submission instructions to avoid processing delays.
    Denial Risk

    PA, Quantity Limits, and Specialty Pharmacy Denial Risk

    PA and QL enforcement is active across the formulary; exceeding quantity limits or failing to obtain PA for PA‑required agents risks claim denial. Specialty (SP) status frequently accompanies PA requirements for high‑cost therapies.

    • Quantity limits may trigger denials if the submitted quantity exceeds the QL without supporting documentation.
    • Specialty pharmacy products often require PA and may be limited to specific fill quantities or sites of care.
    • Failure to obtain PA for PA/SP drugs may result in denial or non‑coverage.
    Step Therapy

    Step Therapy Requirements and Flags

    Step therapy (ST) requirements apply to select products and therapeutic classes. Where ST is indicated, prior trials of preferred agents must be documented before approving non‑preferred therapies.

    • Some anticonvulsants, dermatologic topicals, and other classes include ST requirements.
    • Provider must document trials and outcomes of required first‑line agents to satisfy ST.
    • No single explicit step‑therapy algorithm is embedded in the formulary summary; review drug‑specific lines for ST notes.
    Documentation Required

    Age, New‑Start, and Supply Limit Notes

    Operational notes: some products are age‑limited (AL) or have new‑start supply limits (e.g., opioids new starts limited to 7 days). Ensure the PA request includes age, indication, and justification for requests outside these limits.

    • New start opioid supplies may be limited (e.g., 7‑day supply) — document need for longer duration.
    • Age limits apply to many dermatologic and pediatric agents — include patient age on all requests.
    • When requesting quantities above QL or exceptions for AL, attach clinical rationale and prior course of therapy.

    Key Terms and Formulary Tiering

    inv-102: Formulary tiers
    Formulary tiersDrugs are organized into tiers (Tier 0 through Tier 4) reflecting copayment levels and value; Tier 4 denotes specialty drugs with special handling and fulfillment requirements.
    Tier 0 examplesTier 0 includes certain preventive drugs with no copayment (select oral contraceptives, vitamin D, folic acid, OTC aspirin, smoking cessation products).
    Specialty fulfillmentSpecialty tier drugs may require fulfillment at participating specialty or hemophilia network pharmacies.
    inv-103: Formulary abbreviations
    Common abbreviations listAL = Age Limit; QL = Quantity Limit; PA = Prior Authorization; ST = Step Therapy; NF = Non‑formulary; RX/OTC = Prescription/OTC; SP = Specialty Drug; SF = Split Fill.
    Abbrev usageAbbreviations are used inline on product entries to denote utilization controls and requirements.
    ST explainedST indicates that specified drugs must be tried first prior to coverage of an alternative.
    inv-104: QL definition
    Definition of QLQL (Quantity Limit) — a maximum allowed quantity per time period shown in parentheses (e.g., QL(30 ML daily), QL(2 EA daily)).
    FormatsQL may be expressed per day, per fill, or per multi‑day period (e.g., per 28 days, per 56 days, per 180 days).
    Unit typesUnits include EA (each), ML (milliliters), GM (grams) depending on formulation.
    inv-105: PA definition
    Definition of PAPA (Prior Authorization) — coverage requires approval from the plan before dispensing for products marked 'PA'.
    When requiredPA is noted next to many biologics, specialty, and selected formulations; lack of PA may lead to claim denial.
    Submission noteProviders must submit the Prior Authorization form; urgent requests responded to within 24 hours per documentation guidance.
    inv-106: AL definition
    Definition of ALAL (Age Limit) — minimum (or maximum) age requirement for coverage as noted on product entries (e.g., AL(At least 12 yrs old)).
    ApplicationAge limits must be met and documented when dispensing products with AL annotations.
    Topical examplesMany topical dermatologic products list AL(At least 12 yrs old) for coverage.
    inv-107: New starts limited to 7 day supply
    New‑start supply rule (definition)'New starts limited to 7 day supply' means newly initiated prescriptions for the listed product are limited to a maximum 7‑day supply unless otherwise authorized.
    Applies toUsed primarily for opioid and certain acute analgesic products as indicated on formulary lines.
    Authorization pathwayProviders may request Prior Authorization for longer supplies when clinically justified.
    inv-108: QL(xx EA daily) notation
    QL(xx EA daily) notationQL(xx EA daily) indicates a maximum number of each units (EA) allowed per day for the product (e.g., QL(6 EA daily)).
    InterpretationEA denotes unit count (each) and daily limits are enforced per calendar day unless otherwise specified.
    VariantsSimilar notation used for ML or GM units (e.g., QL(0.3 ML daily), QL(3 GM daily)).
    inv-109: QL (general)
    General QL usageQL denotes a quantity limit applied to a formulary entry; limits may be daily, per fill, or per multi‑day interval and are enforced as listed.
    EnforcementExceeding a QL may trigger claim denial or require Prior Authorization per documentation guidance.
    Unit conventionsUnits used include EA (each), ML (milliliter), and GM (gram) depending on formulation shown in the QL notation.
    inv-110: PA (general)
    PA (general)Prior Authorization (PA) requires clinical review and approval prior to coverage for products marked 'PA' on the formulary.
    Impact of missing PAClaims may be denied if PA is not obtained for products that require it.
    Response timesPA responses: urgent within 24 hours; non‑urgent within 72 hours unless faster response required by law.
    inv-111: ST (general)
    ST (general)ST (Step Therapy) may require trying specified preferred drugs first before Ambetter covers an alternative; entries annotated 'ST' indicate such requirements.
    ExamplesSome product lines (e.g., certain anticonvulsants and topical agents) include 'ST' flags indicating step edits.
    Provider actionDocument trials of required agents when submitting PA or appeals for products subject to ST.
    inv-112: QL abbreviation
    QL abbreviationQL = Quantity Limit (maximum allowed units per time period as shown on formulary entries).
    PurposeIndicates the maximum quantity permitted without additional review or authorization.
    Unit typesMay use EA, ML, GM or per‑fill/period formats depending on product.
    inv-113: PA abbreviation
    PA abbreviationPA = Prior Authorization — approval required before coverage for products marked 'PA'.
    Provider requirementProviders must submit the required PA form and supporting documentation when requested.
    Denial explanationDenied PA requests will include explanation of reasons or missing information.
    inv-114: QL = Quantity Limit
    QL = Quantity LimitQuantity Limit — a maximum allowed quantity per time period shown in parentheses (examples appear across the formulary entries).
    Examples of expressionShown as QL(## EA daily), QL(## ML per 28 day(s) retail), QL(## EA per fill mail), etc.
    Enforcement noteClaims exceeding QL may require Prior Authorization or be denied.
    inv-115: PA = Prior Authorization
    PA = Prior AuthorizationPrior Authorization — coverage requires approval before dispensing for products marked 'PA'.
    When to requestFor non‑formulary drugs or formulary lines annotated 'PA', providers must submit PA prior to dispensing.
    Appeal/denial infoDenied requests will state reasons or missing information to guide resubmission.
    inv-116: ST = Step Therapy
    ST = Step TherapyStep Therapy — a requirement to try specified alternative(s) before coverage of the listed drug is approved (entries annotated 'ST').
    Typical actionProviders should document prior trials of required agents when requesting coverage for an ST‑listed product.
    Examples in formularySeveral topical and systemic products include ST annotations (e.g., clindamycin‑tretinoin).
    inv-117: QL examples
    Stimulant QL examplesExamples include QL(4 EA daily), QL(2 EA daily), QL(3 EA daily) shown for various amphetamine and methylphenidate formulations.
    Unit and age pairingSome stimulant entries pair QL with AL (e.g., AL(At least 6 yrs old)) for pediatric dosing constraints.
    Multi‑format limitsQL formats include daily EA limits and multi‑day ML limits for certain formulations (see specific drug lines).
    inv-118: PA definition (clinical review required)
    PA requires clinical reviewPA indicates clinical review is required before coverage for the listed product (PA = clinical review required).
    SP noteSome entries combine SP and PA indicating site prior authorization or specialty pharmacy involvement is required in addition to PA.
    Provider actionSubmit relevant clinical documentation to support PA requests for specialty/site‑restricted agents.
    inv-119: SP definition (site prior authorization / specialty pharmacy)
    SP definitionSP = Site Prior Authorization or Specialty Pharmacy requirement — additional authorization or dispensing channel required for specialty drugs.
    Fulfillment implicationSpecialty drugs may require dispensing through participating specialty or hemophilia network pharmacies.
    Combined flagsSP often appears alongside PA and QL on antineoplastic and other specialty product lines.
    inv-120: Quantity Limit (definition)
    Quantity Limit (definition)Quantity Limit — maximum allowed units per period as shown on the formulary line (may be daily, per fill, or per multi‑day interval).
    PresentationDisplayed inline as QL(...) next to the product and unit of measure.
    EnforcementExceeding the stated QL may require PA or be denied at claim adjudication.
    inv-121: Prior Authorization (definition)
    Prior Authorization (definition)PA denotes pre‑approval required prior to coverage for the product listed with the PA flag.
    Clinical documentationPA requests should include indication and quantity justification per the drug line requirements.
    Denial handlingDisapproved PA requests will include reasons or identify missing information.
    inv-122: Specialty Pharmacy (definition)
    Specialty Pharmacy (definition)SP indicates specialty pharmacy designation — these drugs may require specialty dispensing and additional handling or site authorization.
    Network requirementSpecialty tier drugs may require fulfillment at participating specialty or hemophilia network pharmacies.
    Associated controlsSP often accompanies PA and QL on formulary entries for specialty agents.
    inv-123: Quantity Limit (definition, alternate)
    Alternate QL definitionQL = maximum allowed units in a defined period (expressed per day, per fill, per 28/56/180 days as shown on the entry).
    Unit examplesCommon units: EA, ML, GM (e.g., QL(8 EA daily); QL(30 ML per 28 day(s))).
    Mail vs retailSome QLs differ between retail and mail channels (explicitly stated where applicable).
    inv-124: Prior Authorization (definition, alternate)
    Prior Authorization (alternate)PA = Authorization required before coverage; commonly applied to specialty, antineoplastic, and select high‑cost agents.
    Site/step combosPA can appear with SP or ST flags indicating combined utilization controls for access.
    Provider guidanceSubmit PA with clinical rationale and documentation to support access for restricted agents.
    inv-125: Specialty Pharmacy designation
    Specialty designationSP = Specialty Pharmacy designation used for drugs that require specialized handling, dispensing, or site authorization.
    Implication for dispensingSP drugs may be limited to participating specialty networks and require PA prior to coverage.
    ExamplesMany antineoplastic and pulmonary hypertension agents carry SP annotations.
    inv-126: AL (Age Limit)
    AL definedAL = Age Limit (e.g., 'AL(At least 12 yrs old)') indicating minimum age for coverage of the product.
    ApplicationUsed frequently for pediatric dosing and topical dermatologic agents.
    DocumentationAge must be documented to support dispensing when AL is present.
    inv-127: QL (definition)
    QL (definition) reiterationQL — Quantity Limit such as QL(3 GM daily) or QL(60 GM per 30 day(s)) shown next to product entries.
    Per‑unit typesUnits of measure include GM, ML, EA and may be expressed per day or per fill period.
    Enforcement noteClaims exceeding QL may require PA or be denied at adjudication.
    inv-128: PA (definition)
    PA (definition) reiterationPA — Prior Authorization required before coverage; annotated next to many topical and systemic agents where applicable.
    ImpactPA annotations indicate need for prior approval to avoid claim denial.
    Example productsClindamycin phosphate‑benzoyl peroxide and some STELARA presentations include PA annotations.
    inv-129: ST (definition)
    ST (definition) reiterationST = Step Therapy — requires trial of specified alternative(s) before the listed product is covered; entries marked 'ST' denote such requirements.
    Topical examplesSeveral topical products (e.g., clindamycin‑tretinoin, clobetasol FOAM) include ST annotations.
    Provider actionDocument prior trials when submitting PA or coverage requests for ST‑flagged products.
    inv-130: QL (definition)
    QL (definition extra)QL — maximum quantity allowed per day or fill as specified; appears inline on formulary entries alongside Tier and ILimits.
    Interpretation guidanceFollow the exact QL notation shown for retail vs mail and per‑period differences.
    ExamplesExamples across entries: QL(4 GM daily), QL(3 GM daily), QL(15.15 GM daily).
    inv-131: PA (definition)
    PA (final reiteration)PA = Prior Authorization — approval required before the drug will be covered; non‑FDA uses may also require PA.
    Non‑FDA usesNon‑FDA approved uses of certain products (e.g., permethrin, ivermectin, spinosad) require PA per formulary notes.
    Denial riskLack of PA for PA‑flagged products may lead to claim denial; denials include reasons/missing information.
    inv-132: ST (definition)
    Initial therapy limit (definition)New starts limited to 7‑day supply — initial prescribing restriction limiting newly initiated prescriptions to 7 days unless authorized.
    Common applicationApplied frequently to opioid and certain butalbital combination products as indicated on the formulary.
    Provider remedyProviders may submit PA to request longer initial supplies when clinically appropriate.

    Initial Prescribing Limits and New-Start Controls

    Initial therapy limits

    Initial therapy is covered subject to the following initial‑use restrictions:

    Initial supply limit for butalbital combos: New starts for certain butalbital‑acetaminophen‑caffeine products are limited to a 7‑day supply; prescribers must request prior authorization for longer courses.7 day supply for new starts

    See butalbital entries

    Initial therapy limits (prescribing restrictions)

    Initial prescribing for opioid and certain analgesic products is covered when ALL conditions below are met:

    New‑start opioid supply restriction: Many opioid products are limited to a 7‑day supply for new starts; prescribers must obtain prior authorization for initial supplies exceeding that limit.7 day supply for new starts

    See opioid product lines showing 'New starts limited to 7 day supply'

    Initial topical acne therapy controls

    Initial coverage for topical acne agents requires ALL of the following:

    Topical acne initial controls: Topical acne products (e.g., clindamycin phosphate‑benzoyl peroxide) require the member to meet any age limits (commonly AL(At least 12 yrs old)), adhere to stated quantity limits (e.g., QL(15 GM per 30 day(s))), and obtain prior authorization when the formulary line indicates 'PA'.

    See topical acne entries for AL/QL/PA specifics

    Initial therapy requirements (high level)

    At initiation, coverage may require any of the following utilization steps:

    Step therapy or PA for topical initiation: Certain topical products are annotated 'ST' or 'PA'; initial coverage may require trial of preferred alternatives (ST) or a prior authorization before the listed product is approved.

    See specific topical entries for ST/PA flags

    Continuation / Ongoing Therapy

    Continuation therapy

    Continuation (ongoing) therapy is covered when ANY of the following apply:

    Continuation therapy notes: For established patients, some products may have different allowable daily QL or require prior authorization for continued higher‑quantity dispensing; the formulary lines imply continuation allowances but specific continuation rules must follow the drug‑line ILimits and PA decisions.

    Continuation implications drawn from QL/PA differences in product lines

    Step Therapy Notes and Affected Products

    Policy pointDetail
    Step Therapy (ST)May require trying a specified preferred drug first before Ambetter covers an alternative; ST is defined in the formulary abbreviations and applied where 'ST' appears next to product entries.
    Product / classST annotation / note
    Fenoprofen calcium tabletsILimits = QL(4 EA daily); ST — step therapy flag shown on product line.
    Product / classUtilization controls noted
    Buprenorphine/naloxone (films, sublingual)Multiple formulations include quantity limits (e.g., QL(2 EA daily), QL values shown) and some lines include PA — indicating utilization controls for opioid partial agonists.
    Product / classST annotation / additional controls
    Eslicarbazepine acetate; Lacosamide (APTIOM) entriesEntries include ST (step therapy) flags (e.g., APTIOM ILimits = QL(2 EA daily); ST; eslicarbazepine acetate ILimits = QL(2 EA daily); ST).
    ObservationImplication
    No explicit multi-step algorithm providedFormulary shows ST flags on product lines but does not include an explicit stepwise algorithm in this excerpt; apply ST where 'ST' is annotated on specific entries.
    Combination productST annotation
    Amlodipine besylate - olmesartan medoxomil (combination)ILimits = ST — combination products may be subject to step therapy as indicated on the product line.
    Drug group / examplesSP / PA / ST notes
    Antineoplastic / specialty agents (multiple entries)Many entries are annotated SP and/or PA (e.g., methotrexate sodium SOLR ILimits = SP; PA); explicit multi-step ST sequences are not provided in this excerpt — specialty/PA requirements control access.
    AnnotationMeaning / example
    SP; PAIndicates specialty pharmacy or site prior authorization plus prior authorization may be required; some entries list 'SP; PA' suggesting step/ specialty process prior to coverage.
    ProductUtilization control / ST context
    UPTRAVI titration packILimits = max fill(s_perl 180 dayls) on titration pack (utilization control); UPTRAVI tablets (200 mcg) ILimits = PA — utilization controls applied; explicit ST sequence not shown.
    TopicalST / ILimits example
    Sulfacetamide sodium with sulfur liquid; Tretinoin; Clobetasol propionate (topicals)Several topical products include ST annotations (e.g., sulfacetamide sodium wl sulfur ILimits = AL(At least 12 yrs old); ST; clobetasol propionate FOAM ILimits = QL(3 GM daily); ST).
    ContextUsage of ST annotation on product entries
    ST on product entriesProducts such as clobetasol propionate FOAM and GEL show 'ST' alongside QL and PA in some formulations; the ST annotation on a product line indicates a step edit exists and requires trial of preferred alternatives as documented.
    AnnotationInterpretation / example
    SP; PA on formulary rowsSome products are listed as 'SP; PA' which indicates a step or specialty requirement prior to prior authorization — i.e., step edits or specialty-channel requirements may be enforced before PA is granted.

    Quantity Limits by Product (Selected Examples)

    inv-150: Various stimulant and other listed products (QL examples)
    Various stimulant and other QL examplesExamples include QL(4 EA daily); QL(2 EA daily); QL(30 ML daily); QL(280 ML per 56 days) as shown across stimulant and other entries.
    Unit diversityQL values use EA, ML, GM and per‑period expressions depending on drug and formulation.
    See product lineExact QL must be read from each formulary product line for enforcement and documentation.
    inv-151: Opioid medications (new starts)
    Opioid new‑start summaryTwo 7‑day fills in any 28‑day period; up to 28 non‑consecutive days in any 90‑day period for opioid medications marked 'New starts limited to 7 day supply'.
    Applies cumulativelyThe limit applies cumulatively to all opioid medications filled by the member.
    PA for excessFills exceeding these limits require Prior Authorization submission.
    inv-152: Multiple examples across lines
    Multiple inline examplesDocument contains many inline QL/PA/ST examples across drug lines; refer to each product entry for exact QL syntax and values.
    Ivermectin/EMVERM exampleEMVERM CHEW QL(2 EA daily; 6 EA per fill retail; 6 per fill mail); 1 max.
    Starter kit/package examplesCYLTEZO/HUMIRA starter kits show package(s) per 180 day(s) retail and max fill(s) per 180 day(s) rules.
    inv-154: ivermectin / EMVERM CHEW QL example
    EMVERM / ivermectin exampleEMVERM CHEW and related ivermectin entries include QL(2 EA daily; 6 EA per fill retail; 6 per fill mail); 1 max (EMVERM) and ivermectin entries show QL up to 9 EA per retail/mail with varying period limits).
    Max fill variabilityIvermectin listings show multiple QL presentations (daily EA and per‑fill mail/retail limits; some show 1 max fill per defined days).
    PA noteSome ivermectin/prq entries include PA for non‑FDA uses as indicated elsewhere in the formulary.
    inv-155: lacosamide SOLN IV 200 (APTIOM) QL
    Lacosamide IV exampleLacosamide SOLN IV (APTIOM) listed with QL(40 ML daily).
    APTIOM tablet QLsAPTIOM tablet entries show QL(2 EA daily) or other tablet QLs depending on strength and pack type.
    ST/PA flagsSome lacosamide entries include ST or PA annotations on specific presentations.
    inv-156: DIACOMIT CAPS 250 MG QL
    DIACOMIT CAPS QLDIACOMIT CAPS 250 MG listed with QL(12 EA) (per formulary entry).
    Alternate DIACOMIT QLsOther DIACOMIT pack/tablet presentations show differing QL values (e.g., QL(6 EA daily) for packs).
    PA associationSome DIACOMIT presentations include PA annotations where noted.
    inv-157: topiramate CPSP 15 MG QL
    Topiramate CPSP 15 MGtopiramate CPSP 15 MG listed with QL(6 EA daily).
    Other topiramate QLsTopiramate tablet strengths show QL variants (e.g., QL(4 EA daily) for some strengths, QL(2 EA daily) for others).
    PA for some formsCertain controlled‑release or specialty presentations may carry PA flags per the formulary.
    inv-158: gabapentin SOLN QL
    Gabapentin SOLN QLgabapentin SOLN listed with QL(60 ML).
    Gabapentin tablet entriesTablet formulations have different QL annotations or none depending on strength and presentation.
    Usage noteFollow the specific QL shown for solution vs tablet formulations when adjudicating claims.
    inv-159: DILANTIN INFATABS CHEW QL
    DILANTIN INFATABS CHEW QLDILANTIN INFATABS CHEW entries include QL(6 EA daily).
    Hydantoins class noteHydantoin family entries include varying QLs and may include SP/PA annotations for certain presentations.
    EnforcementAdhere to the QL per formulation when dispensing chewable vs tablet forms.

    Specialty Pharmacy and Site Restrictions

    Billing Rule

    Arrange specialty pharmacy fulfillment for Tier‑4/specialty drugs

    Specialty tier drugs may require fulfillment at participating specialty or hemophilia network pharmacies; providers should arrange dispensing through an in‑network specialty pharmacy when SP is indicated.

    • If a product is on the specialty tier (Tier 4) and notes specialty fulfillment, confirm an in‑network specialty or hemophilia pharmacy will dispense.
    • Contact the payer or check the Ambetter website pharmacy information for participating specialty pharmacies.
    Note

    No explicit site‑of‑care restrictions present in extract

    The extract contains no explicit site‑of‑care restrictions; when no site restriction is listed, usual dispensing or administration settings apply unless otherwise noted on the product row.

    • If no site‑of‑care limitation appears on the formulary row, follow standard site‑of‑care practices unless payer guidance indicates otherwise.
    • Confirm site‑of‑care requirements for specific agents if clinical circumstances suggest specialty administration is needed.
    Billing Rule

    Coordinate specialty pharmacy or infusion‑center requirements for SP‑flagged agents

    Some agents are designated 'SP' or 'Site Prior Authorization' indicating specialty pharmacy or infusion/infusion‑center site‑of‑care restrictions; providers must arrange dispensing/administration per those annotations.

    • SP or 'Site Prior Authorization' flags may require infusion center administration or specialty pharmacy dispensing—confirm and coordinate prior to scheduling treatment.
    • Obtain any site prior authorization if required for infusion or clinic administration of the listed agent.
    Billing Rule

    Use specialty pharmacy dispensing for agents with 'SP' designation

    An 'SP' designation on a formulary row indicates specialty pharmacy dispensing is required for that agent; providers should route prescriptions to an in‑network specialty pharmacy when SP is shown.

    • Examples: multiple antineoplastic and specialty agents show SP—confirm specialty dispensing channel and PA prior to prescribing.
    • Failure to dispense via the required specialty pharmacy may result in non‑coverage.

    Formulary Purpose and Scope

    The formulary lists FDA‑approved brand and generic drugs covered under the prescription benefit and explicitly states that generic drugs are considered first-line treatment when available. The list is periodically reviewed and may omit certain dosage forms or strengths; providers should confirm plan benefit limits and any per‑product utilization controls (for example, QL, PA, AL, ST) before prescribing or dispensing.

    Biosimilar / Brand Mappings

    Billing Rule

    Follow listed brand/biosimilar mapping (e.g., fludarabine SOLN → MVASI)

    Formulary rows may show a brand/prug Name mapping (example: fludarabine phosphate SOLN listed with prug Name MVASI); use the listed mapping when confirming biosimilar/brand relationships for billing or PA.

    • Fludarabine phosphate SOLN lists prug Name = MVASI and ZIRABEV—note these mappings when preparing PA or specialty pharmacy requests.
    • Reference the formulary's prug Name entries to ensure correct product identification on claims and PA forms.